血清SA，EMA和GPDA单项及联合检测对胃癌诊断的临床研究
|
摘要
目的:通过检测和分析非萎缩性胃炎、胃癌前病变及胃癌患者血清中SA、EMA和GPDA的浓度,并比较其与胃癌临床生物学行为的关系,以探讨血清SA,EMA和GPDA单项及联合检测对胃癌的诊断价值。
方法:采用酶速率法、酶联免疫吸附试验法(ELISA)、连续监测法分别对经电子胃镜及病理检查确诊的30例胃癌患者、25例胃癌前病变患者及35例非萎缩性胃炎的血清SA、EMA、GPDA进行测定,进行两两比较,分析血清SA、EMA和GPDA单项及联合检测胃癌的敏感性,特异性,诊断准确度和阳性似然比。同时分析胃癌患者血清SA、EMA、GPDA与胃癌临床生物学行为的关系。所有资料用SPSS13.0统计学软件进行处理。
结果:胃癌组血清SA、GPDA浓度明显高于非萎缩性胃炎、胃癌前病变组(P<0. 05 ),单项检测中以SA较敏感(50.00%),GPDA的特异性(97.14%)和诊断准确度(90.99%)较高,且诊断价值较大(LR+ =11.65)。联合检测SA,GPDA可以提高诊断敏感性(53.33%)。血清EMA对胃癌诊断没有统计学意义(P>0.05)。非萎缩性胃炎组GPDA与年龄有统计学意义(P<0.05), SA浓度在肿瘤分化程度组差别有统计学意义(P<0.05)外,其余各组与临床生物学行为均无统计学意义(P>0. 05)。
结论:检测血清SA和GPDA对于胃癌的诊断有重要参考价值。SA和GPDA的联合检测可提高胃癌诊断的准确性。检测血清EMA对胃癌诊断可能没有价值。胃癌患者血清SA, GPDA与胃癌临床生物学行为有一定关系,检测血清SA,GPDA将可能有助于判断胃癌的转移、复发及监测预后。非萎缩性胃炎组血清GPDA与年龄有关。
Objective:We intend to analyse and detect the expression of serum SA, EMA and GPDA with non-atrophic gastritis, gastric precancerous lesions and gastric cancer in patients and analyse the relationships among them, and this paper also analyzes the relationship with the biology behavior of gastric carcinoma, in order to evaluate the values of alone and combinative measurements of serum SA, EMA and GPDA in the diagnosis of gastric cancer.
Methods:We apply enzyme kinetic assay,continuous monitoring and ELISA methods to detect serum SA,EMA and GPDA in 30 cases of patients with gastric cancer patients ,25 cases of patients with gastric precancerous lesions and 35 cases of patients with non-atrophic gastritis with electronic gastroscope and pathological examination confirmed, compare the relevance of the groups,and then the sensitivity, specificity, diagnosis accuracy and positive likelihood ratio were calculated about alone and combinative measurements of the markers in the diagnosis of gastric cancer. and analyze the relationship between the expressions of them and clinical biology of gastric carcinoma .All dates were processed by SPSS 13.0 analysis software .
Results:The serum concentrations of SA and GPDA in gastric carcinoma are remarkably higher than those in non-atrophic gastritis and gastric precancerous lesions (P< 0.05 ). A single detection of SA in the most sensitive (50.00%), GPDA the highest specificity (97.14%), one of the diagnostic accuracy GPDA the highest (90.99%), and the greatest diagnostic value (LR += 11.65). Joint detection SA, GPDA can improve the diagnostic sensitivity (53.33%), serum EMA is not a valuable marker in the diagnostic of gastric cancer(P>0.05). The concentrations of GPDA in non-atrophic gastritis group are age-related (P <0.05) and the concentrations of SA in the invasion stage is obviously higher than the localized stage (P<0.05), There are no obvious correlations between the levels of the other groups with the clinical biology behavior of gastric carcinoma(P>0.05). Conclusion:It has an important reference value for the diagnosis of gastric cancer to detect serum SA and GPDA. the Joint Detection SA and GPDA can improve the accuracy of the diagnosis of gastric cancer. EMA serum possibly has no diagnostic value for gastric cancer. The expressions of SA,GPDA in serum are related to the biology behaviors of gastric carcinoma, and to test the concentrations of SA,GPDA in serum is helpful in judging metastasis and recrudescence, and monitoring prognosis. serum GPDA levels in non-atrophic gastritis group increased with age.
方法:采用酶速率法、酶联免疫吸附试验法(ELISA)、连续监测法分别对经电子胃镜及病理检查确诊的30例胃癌患者、25例胃癌前病变患者及35例非萎缩性胃炎的血清SA、EMA、GPDA进行测定,进行两两比较,分析血清SA、EMA和GPDA单项及联合检测胃癌的敏感性,特异性,诊断准确度和阳性似然比。同时分析胃癌患者血清SA、EMA、GPDA与胃癌临床生物学行为的关系。所有资料用SPSS13.0统计学软件进行处理。
结果:胃癌组血清SA、GPDA浓度明显高于非萎缩性胃炎、胃癌前病变组(P<0. 05 ),单项检测中以SA较敏感(50.00%),GPDA的特异性(97.14%)和诊断准确度(90.99%)较高,且诊断价值较大(LR+ =11.65)。联合检测SA,GPDA可以提高诊断敏感性(53.33%)。血清EMA对胃癌诊断没有统计学意义(P>0.05)。非萎缩性胃炎组GPDA与年龄有统计学意义(P<0.05), SA浓度在肿瘤分化程度组差别有统计学意义(P<0.05)外,其余各组与临床生物学行为均无统计学意义(P>0. 05)。
结论:检测血清SA和GPDA对于胃癌的诊断有重要参考价值。SA和GPDA的联合检测可提高胃癌诊断的准确性。检测血清EMA对胃癌诊断可能没有价值。胃癌患者血清SA, GPDA与胃癌临床生物学行为有一定关系,检测血清SA,GPDA将可能有助于判断胃癌的转移、复发及监测预后。非萎缩性胃炎组血清GPDA与年龄有关。
Objective:We intend to analyse and detect the expression of serum SA, EMA and GPDA with non-atrophic gastritis, gastric precancerous lesions and gastric cancer in patients and analyse the relationships among them, and this paper also analyzes the relationship with the biology behavior of gastric carcinoma, in order to evaluate the values of alone and combinative measurements of serum SA, EMA and GPDA in the diagnosis of gastric cancer.
Methods:We apply enzyme kinetic assay,continuous monitoring and ELISA methods to detect serum SA,EMA and GPDA in 30 cases of patients with gastric cancer patients ,25 cases of patients with gastric precancerous lesions and 35 cases of patients with non-atrophic gastritis with electronic gastroscope and pathological examination confirmed, compare the relevance of the groups,and then the sensitivity, specificity, diagnosis accuracy and positive likelihood ratio were calculated about alone and combinative measurements of the markers in the diagnosis of gastric cancer. and analyze the relationship between the expressions of them and clinical biology of gastric carcinoma .All dates were processed by SPSS 13.0 analysis software .
Results:The serum concentrations of SA and GPDA in gastric carcinoma are remarkably higher than those in non-atrophic gastritis and gastric precancerous lesions (P< 0.05 ). A single detection of SA in the most sensitive (50.00%), GPDA the highest specificity (97.14%), one of the diagnostic accuracy GPDA the highest (90.99%), and the greatest diagnostic value (LR += 11.65). Joint detection SA, GPDA can improve the diagnostic sensitivity (53.33%), serum EMA is not a valuable marker in the diagnostic of gastric cancer(P>0.05). The concentrations of GPDA in non-atrophic gastritis group are age-related (P <0.05) and the concentrations of SA in the invasion stage is obviously higher than the localized stage (P<0.05), There are no obvious correlations between the levels of the other groups with the clinical biology behavior of gastric carcinoma(P>0.05). Conclusion:It has an important reference value for the diagnosis of gastric cancer to detect serum SA and GPDA. the Joint Detection SA and GPDA can improve the accuracy of the diagnosis of gastric cancer. EMA serum possibly has no diagnostic value for gastric cancer. The expressions of SA,GPDA in serum are related to the biology behaviors of gastric carcinoma, and to test the concentrations of SA,GPDA in serum is helpful in judging metastasis and recrudescence, and monitoring prognosis. serum GPDA levels in non-atrophic gastritis group increased with age.
引文
[1]陈锡美,许树长.胃癌的临床表现.胃粘膜疾病基础与临床研究[M] .2004,1;204-205.
[2]吉亚南,宋静慧.EMA和CK在上皮肿瘤微转移的应用.内蒙古医学杂志[J] 2006,38(3):257-258
[3]施平凡.血清GPDA测定对肝血管瘤与肝癌鉴别诊断的价值,天津医[J]1998,26(1):29
[4]丛静波,王志华,牛爱军,等.血清苷氨酰脯氨酸二肽氨基肽酶对胃癌诊断价值的探讨.上海医学检验杂志[J],2002 ,17 (2) :75-76
[5]中华医学会消化病学分会.中国慢性胃炎共识意见[J ] .胃肠病学,2006 ,11 (11) : 674 - 684.
[6]陈锡美,许树长。胃癌概述。胃粘膜疾病基础与临床研究[M]。2004,1;163.
[7]李春海.加强肿瘤生物学标志的研究.中华检验学杂志[J],2000;23(1):6-8
[8] Kodama I .The clinical efficacy of CA72-4 as serum marker for gastic cancer in comparison with CA 19 -9 and CEA.Int J Surg,1995;80(1):45一48
[9] Shen G J,Datta A K,Izumi M,et al.Expression of a-2,9/a-2,8-polysialytransferase from Esch- erichia coli K92[J].J Biol Chem,1999,274(49):35139-35146
[10] NakajimaK ,Ochiai T ,Su zuki T ,et al .Impact of preoperative serum CEA,CA19-9,AFP lev- els in gastric cancer patients.Tumour Bio1,1998,19(6 ):464一469
[11] Tucchi T ,Costa G ,Lepre L , et al .The role of serum and gastric juice levels of CEA CA19- 9,CA 72一4 in patients with gastirc cancer.J Cancer Res Clin Oncol,1998, 128( 8);4 50一455
[12]许英萍,吕宾,项柏康等.血清唾液酸水平对消化道恶性肿瘤诊断价值的探讨[J].杭州医学高等专科学校学报,2000,21(7):16—18
[13]张柱,金晓明,张敏,等.消化系统癌症患者血清脂结合唾液酸水平分析[J].福建医药杂志,1978,9(5):28-29
[14]万德森,临床肿瘤学[M].北京:科学出版社,1999.64-65
[15] Ronald A. Delellis, Ricardo V. Lloyd, Philill U. Heitz,Charis Eng. WHO classification[J]. Pathology andg enetics of Tumours of Endocrine Organs,2004, 51-61
[16] Kilicarslan B, Pesterelli EH et al .Epithelial membrane and S-100 protein expression in benign and malignant papillary thyroid neoplasms. Adv Clin Path[J]. 2000 ,4(4):155-158
[17]田丰秋,吕丽等.CK19,P53,P63,EMA, P170蛋白在甲状腺乳头状癌中的表达及病理意义.大连医科大学学报[J],2007,29(2):103—104
[18]部永顺,王庆兆等.滤泡状甲状腺肿瘤中CD57,EMA的表达.郑州大学学报(医学版)[J] 2002,37(4):409—411
[19] Soetrisrm E ,Tjahjadi G .Pathological aspect of brain tumors.Gan To Kagaku Kyoho. 2000. 27 (suppl 2):274
[20]庄建华,李焰生等上皮膜抗原免疫细胞化学检查在脑膜癌病中的诊断价值[J] J Clin Neurol 2005,18(1):54-56
[21]胡云,膝长波.联合检测子宫内膜中DNA,CEA,EMA,KT及端粒酶诊断子宫内膜癌.解放军保健医学杂志[J].2001,3(3):170-172
[22] Kir G, Cetiner H, Gurbuz A, Karateke A.The value of epithelial membrane antigen overexpre -ssion in hyperplastic and malignant endometrium and its relationship with steroid hormone receptor expression. Eur J Gynaecol Oncol[J]. 2004;25(4):502-505
[23] Coronado PJ, Fasero M et al.A comparison of epitthelial membrane antigen overexpression in benign and malignant endometrium. Gynecol Oncol[J]. 2001,82(3):483-488
[24] Bamias A, Chorti M et al.Prognostic significance of CA125,CD44,and epithelial membrane antigen in renal cell carcinoma. Urology[J]. 2003 ,62(2):368-373
[25] Mariko O, Sotoh T et al. Eccrine porocarcinoma with Bowenoid changes: epithelial membrane antigen is not a useful marker for malignant tumors arise from eccrine gland structures. Acta Derm Venereol[J]. 2004,84(2):142-144
[26] Tsuzuki T, Ujihira N, Ando T.Usefulness of epithelial membrane antigen(EMA) to discriminate between Perineural invasion and perineural indentation in prostatic carcinoma. Histopatho -logy [J]. 2005;47(2):159-165
[27]徐永成,陈奇奥,孙敏.血清CEA、CA199、CA724和EMA联检对胃癌的诊断价值.放射免疫学杂志[J]2007,20(3):285-286
[28]曹兴建,谢晓谦,王逸民.甘氨酰脯氨酸二肽氨基肽酶测定及其应用.临床检验杂志[J] . 1993;11 :4
[29]施平凡,郭亚洲,黄新,等.血清GPDA在原发性肝癌诊断中的应用.中国肿瘤临床[J] , 1998 ,25 (4) :287-288
[30]劳明,朱波,黄文成,等.三种肿瘤标志物联合检测对原发性肝癌的诊断价值.中华消化杂志[J],2005 ,25 (2) :109-110
[31] Liu HD, Ni RZ, Xiao MB et al. Clinical significance of serum GPDA-F determined by immu -noelectrophoresis in diagnosis of hepatocellular carcinoma. Ai Zheng[J] 2006;25(2):247-249
[32] Li M, Ni R, Huang J et al. The value of serum GPDA-F for the diagnosis of primary hepatoce -llular carcinoma.Zhonghua Gan Zang Bing Za Zhi[J] 2000;8(3):139-141
[33]劳明,黄玲莎等.胃癌患者Hp感染及血清GPDA活性的变化.肿瘤防治研究[J] 2006,33 (5):358-360
[34]倪语星.革兰阴性菌内酰胺酶的耐药性问题.中华检验医学杂志[J], 2001,24:201～203
[35]中华人民共和国卫生部医政司.全国临床检验操作规程[S].第2版.南京:东南大学出版社.1997:452～471.
[36] National Committee for Clinical Laboratory Standards. Performance Standards for Antimicr-bial susceptibility testing; twelfth informa- tional supplement[S]. M100- S12. Pennsylvania: NCCLS, 2002.1～113
[37]卢忠,卢加荪.GPDA与胃癌发展关系.浙江临床医学[J],2002,4(5):354
[38]贺蓉,曹友德.胃癌患者血清GPDA的检测及其诊断价值.实用预防医学[J],2002,9(2):153-154
[39]项国谦,张卫英等.SA,GPDA检测对胃癌诊断的临床价值.浙江中西医结合杂志[J],2005,47(2):92-93
[1]郑莹,李德,徐耀昌.上海市胃癌发病率和死亡率的变化与预测[J].外科理论与实践,2000,5(31):152-154.
[2] Bando E, Yonemura Y, Tabesbita Y, et al. Int raoperat ive lavage fo r cytological examination in 1297 patients with gast ric carcinoma [J ]. Am J Surg, 1999,178(3): 256- 262.
[3] Duraker N , Celik AN. The p rogno st ic significance of preoperative serum CA19 -9 in pat ients with respectable gast ric carcinoma: comparison w ith CEA[J].J Surg Oncol, 2001, 76 (4) : 266- 271.
[4] M arrelli D, P into E, De Stefano A , et al. Preoperative posit ivity of serum tumor markers in a strong predictor of hematogenous recurrence of gastric caner [J ]. J Surg O nco l, 2001, 78 (4) : 253- 258.
[5] N akata B, H irakaw a YS, Chung K, et al. SerumCA 125 level as a p redictor of peritoneal dissemination in patientsw ith gastric carcinoma [J ]. Cancer,1998,83 (12) : 2488- 2492.
[6] Pectasides D, Mylonalakis A , Kostopoulou M , et al.CEA , CA 1929, and CA 250 in monitor- ing gastric carcinoma [J ]. Am J Clin O ncol, 1997, 20 (4) : 348 -353.
[7] Pectasides D, M ylonalak is A , Ko stopoulouM , et al.CEA , CA 19-9, and CA 50 in monitoring gastric carcinoma [J ]. Am J Clin Oncol, 1997, 20 (4) : 348 -353.
[8] Nakata B, Chung K, M uguruma K, et al. Changes in tumo r marker levels as a predictor of chemotherapeutic effect in patients with gastric carcinoma [J ]. Cancer, 1998, 83 (1) : 19- 24.
[9] GasparMJ, A rribas I, CocaMC, et al. Prognostic value of carcinoembryonic antig- en, CA 19- 9 and CA 72-4in gast ric carcinoma [J ]. Tumor Biol, 2001, 22 (5) :318- 322
[10] ColcherD, Hand PH,Nuti M, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells [ J ]. Proc Natl Acad Sci USA, 1981, 78 (5) : 3199-3203.
[11]张涛,袁振铎,张鑫.肿瘤标志物志朽CA72-4在胃癌诊断中的意义[J].中级医刊. 1998, 33;43-35.
[12]赵继宗,詹义华,陈规划等.血清肿瘤相关糖蛋白72的临床应用探讨[J].中国胃肠外科杂志,1999;2:177-179.
[13]陈玉,林庚金.血清CA72-4测定鉴别胃良、恶性病变的价值[J].中国内镜杂志,1999;5:37.
[14]Tian Xuezhi,AnM ei,Zhang Yan.V alue and significance of C A19-9 and CEA in serum of patients with gastrointestinal cancer[J].C ancer Research and Clinic , 2000,12(1):17-18.
[15]TocchiT ,Costa G ,Lepte L ,et al .The role of serum and gastric juice levels of CE-A,CA19-9, C A72-4 in patients with gastric cancer[J ]. J Cancer Res Ciln Oncol, 1998 ,124( 8):450- 455.
[16]施平凡.血清GPDA测定对肝血管瘤与肝癌鉴别诊断的价值[J].天津医药.1998,26(1):29
[17]丛静波,王志华,牛爱军,等.血清苷氨酰脯氨酸二肽氨基肽酶对胃癌诊断价值的探讨[J].上海医学检验杂志,2002 ,17 (2) :75-76.
[18] Liu HD, Ni RZ, Xiao MB et al. Clinical significance of serum GPDA-F determined by immu -noelectrophoresis in diagnosis of hepatocellular carcinoma. Ai Zheng[J] 2006; 25 (2):247-249.
[19] Li M, Ni R, Huang J et al. The value of serum GPDA-F for the diagnosis of primary hepatoce -llular carcinoma.Zhonghua Gan Zang Bing Za Zhi[J] 2000;8(3):139-141.
[20] Ren J ,Chen Z ,Fan DM,et al . Defection of circulating gastric carcinoma associated antigen MG7 - Ag in human sera using an established single determinant immuno - polymerase chain reaction technique[J ] . Cancer ,2000 ,88 (2) :280.
[21]姚生华,沈江帆.胃癌MG抗原IRMA临床应用价值的初步探讨[J].放射免疫学杂志,1996, 9(3):133
[22]Samloff M. Pepsinogen I and II : purification from gastric mucosa and radio immunoassay in serum [J ].Gast roenterology, 1982, 82 (1) : 26- 33.
[23]蒋孟军,肖志坚.胃癌患者血清胃蛋白酶原含量的检测及其临床意义[J].实用癌症杂志, 2000, 15 (1) : 40- 42.
[24] Paula J Waters et al .Ann clin biodom 1992:29;627-637.
[25]陈建华,徐勇,郑晓丰等.血清唾液检测对诊断消化性肿瘤的临床应用[J].实用临床医学.2007,8(6):28-30.
[26]徐永成,陈奇奥,孙敏.血清CEA、CA199、CA724和EMA联检对胃癌的诊价值[J].放射免疫学杂志[J]2007,20(3):285-286.
[27]王开明.胃癌的早期诊断和治疗进展[J]浙江临床医学,2002,4(6): 401.
[28]张汝建,卢兴梅,韩信义.胃癌HP感染与PCNA表答的关系系[J]山东医药,1998,38(6): 10.
[29]王涛,张蓓,王占民.人体胃癌及癌前病变p53和PCNA的免疫组化研究[J]山东医科大学学报,1998,36(3):246～249.
[30]Kang YH ,Lee HS,Kin W H .Promoter methylation and silencing of PTEN in gastric carcinoma.Lab Invest,2002,82(3):285—291.
[31]刘芬,于皆平,邓全军,等. PTEN在胃癌细胞中的表达及其CpG岛甲基化状态的研究[J ].肿瘤防治研究, 2006, 33 (9):632-634.
[32]Yang L,,Kuang LG,Zheng HC,et a1.PTEN encoding product:a marker for tumorigenesis and progression of gastric carcinoma .World J Gasroenterol,2003,9(1):35,39.
[33]刘蒿翎,陈振依.p53基因突变与早期谚断胃癌的研究[J]广西医学,1998,20(3):381～383.
[34]Wang W,Luo HS,Yu BP. Expression of NF2kappaB and human telomerase reverse transcri -ptase in gastric cancer and precancerous lesions[J]. World J Gastroenterol ,2004 ,10:177 - 181.
[35]Ahn MJ.Nob YH,Lee YS,et a1.Telomemse activity and its clinicopathological significance in gastric Cance[j] Eur J Cancer.1997.33(8):1309～131 3.
[2]吉亚南,宋静慧.EMA和CK在上皮肿瘤微转移的应用.内蒙古医学杂志[J] 2006,38(3):257-258
[3]施平凡.血清GPDA测定对肝血管瘤与肝癌鉴别诊断的价值,天津医[J]1998,26(1):29
[4]丛静波,王志华,牛爱军,等.血清苷氨酰脯氨酸二肽氨基肽酶对胃癌诊断价值的探讨.上海医学检验杂志[J],2002 ,17 (2) :75-76
[5]中华医学会消化病学分会.中国慢性胃炎共识意见[J ] .胃肠病学,2006 ,11 (11) : 674 - 684.
[6]陈锡美,许树长。胃癌概述。胃粘膜疾病基础与临床研究[M]。2004,1;163.
[7]李春海.加强肿瘤生物学标志的研究.中华检验学杂志[J],2000;23(1):6-8
[8] Kodama I .The clinical efficacy of CA72-4 as serum marker for gastic cancer in comparison with CA 19 -9 and CEA.Int J Surg,1995;80(1):45一48
[9] Shen G J,Datta A K,Izumi M,et al.Expression of a-2,9/a-2,8-polysialytransferase from Esch- erichia coli K92[J].J Biol Chem,1999,274(49):35139-35146
[10] NakajimaK ,Ochiai T ,Su zuki T ,et al .Impact of preoperative serum CEA,CA19-9,AFP lev- els in gastric cancer patients.Tumour Bio1,1998,19(6 ):464一469
[11] Tucchi T ,Costa G ,Lepre L , et al .The role of serum and gastric juice levels of CEA CA19- 9,CA 72一4 in patients with gastirc cancer.J Cancer Res Clin Oncol,1998, 128( 8);4 50一455
[12]许英萍,吕宾,项柏康等.血清唾液酸水平对消化道恶性肿瘤诊断价值的探讨[J].杭州医学高等专科学校学报,2000,21(7):16—18
[13]张柱,金晓明,张敏,等.消化系统癌症患者血清脂结合唾液酸水平分析[J].福建医药杂志,1978,9(5):28-29
[14]万德森,临床肿瘤学[M].北京:科学出版社,1999.64-65
[15] Ronald A. Delellis, Ricardo V. Lloyd, Philill U. Heitz,Charis Eng. WHO classification[J]. Pathology andg enetics of Tumours of Endocrine Organs,2004, 51-61
[16] Kilicarslan B, Pesterelli EH et al .Epithelial membrane and S-100 protein expression in benign and malignant papillary thyroid neoplasms. Adv Clin Path[J]. 2000 ,4(4):155-158
[17]田丰秋,吕丽等.CK19,P53,P63,EMA, P170蛋白在甲状腺乳头状癌中的表达及病理意义.大连医科大学学报[J],2007,29(2):103—104
[18]部永顺,王庆兆等.滤泡状甲状腺肿瘤中CD57,EMA的表达.郑州大学学报(医学版)[J] 2002,37(4):409—411
[19] Soetrisrm E ,Tjahjadi G .Pathological aspect of brain tumors.Gan To Kagaku Kyoho. 2000. 27 (suppl 2):274
[20]庄建华,李焰生等上皮膜抗原免疫细胞化学检查在脑膜癌病中的诊断价值[J] J Clin Neurol 2005,18(1):54-56
[21]胡云,膝长波.联合检测子宫内膜中DNA,CEA,EMA,KT及端粒酶诊断子宫内膜癌.解放军保健医学杂志[J].2001,3(3):170-172
[22] Kir G, Cetiner H, Gurbuz A, Karateke A.The value of epithelial membrane antigen overexpre -ssion in hyperplastic and malignant endometrium and its relationship with steroid hormone receptor expression. Eur J Gynaecol Oncol[J]. 2004;25(4):502-505
[23] Coronado PJ, Fasero M et al.A comparison of epitthelial membrane antigen overexpression in benign and malignant endometrium. Gynecol Oncol[J]. 2001,82(3):483-488
[24] Bamias A, Chorti M et al.Prognostic significance of CA125,CD44,and epithelial membrane antigen in renal cell carcinoma. Urology[J]. 2003 ,62(2):368-373
[25] Mariko O, Sotoh T et al. Eccrine porocarcinoma with Bowenoid changes: epithelial membrane antigen is not a useful marker for malignant tumors arise from eccrine gland structures. Acta Derm Venereol[J]. 2004,84(2):142-144
[26] Tsuzuki T, Ujihira N, Ando T.Usefulness of epithelial membrane antigen(EMA) to discriminate between Perineural invasion and perineural indentation in prostatic carcinoma. Histopatho -logy [J]. 2005;47(2):159-165
[27]徐永成,陈奇奥,孙敏.血清CEA、CA199、CA724和EMA联检对胃癌的诊断价值.放射免疫学杂志[J]2007,20(3):285-286
[28]曹兴建,谢晓谦,王逸民.甘氨酰脯氨酸二肽氨基肽酶测定及其应用.临床检验杂志[J] . 1993;11 :4
[29]施平凡,郭亚洲,黄新,等.血清GPDA在原发性肝癌诊断中的应用.中国肿瘤临床[J] , 1998 ,25 (4) :287-288
[30]劳明,朱波,黄文成,等.三种肿瘤标志物联合检测对原发性肝癌的诊断价值.中华消化杂志[J],2005 ,25 (2) :109-110
[31] Liu HD, Ni RZ, Xiao MB et al. Clinical significance of serum GPDA-F determined by immu -noelectrophoresis in diagnosis of hepatocellular carcinoma. Ai Zheng[J] 2006;25(2):247-249
[32] Li M, Ni R, Huang J et al. The value of serum GPDA-F for the diagnosis of primary hepatoce -llular carcinoma.Zhonghua Gan Zang Bing Za Zhi[J] 2000;8(3):139-141
[33]劳明,黄玲莎等.胃癌患者Hp感染及血清GPDA活性的变化.肿瘤防治研究[J] 2006,33 (5):358-360
[34]倪语星.革兰阴性菌内酰胺酶的耐药性问题.中华检验医学杂志[J], 2001,24:201～203
[35]中华人民共和国卫生部医政司.全国临床检验操作规程[S].第2版.南京:东南大学出版社.1997:452～471.
[36] National Committee for Clinical Laboratory Standards. Performance Standards for Antimicr-bial susceptibility testing; twelfth informa- tional supplement[S]. M100- S12. Pennsylvania: NCCLS, 2002.1～113
[37]卢忠,卢加荪.GPDA与胃癌发展关系.浙江临床医学[J],2002,4(5):354
[38]贺蓉,曹友德.胃癌患者血清GPDA的检测及其诊断价值.实用预防医学[J],2002,9(2):153-154
[39]项国谦,张卫英等.SA,GPDA检测对胃癌诊断的临床价值.浙江中西医结合杂志[J],2005,47(2):92-93
[1]郑莹,李德,徐耀昌.上海市胃癌发病率和死亡率的变化与预测[J].外科理论与实践,2000,5(31):152-154.
[2] Bando E, Yonemura Y, Tabesbita Y, et al. Int raoperat ive lavage fo r cytological examination in 1297 patients with gast ric carcinoma [J ]. Am J Surg, 1999,178(3): 256- 262.
[3] Duraker N , Celik AN. The p rogno st ic significance of preoperative serum CA19 -9 in pat ients with respectable gast ric carcinoma: comparison w ith CEA[J].J Surg Oncol, 2001, 76 (4) : 266- 271.
[4] M arrelli D, P into E, De Stefano A , et al. Preoperative posit ivity of serum tumor markers in a strong predictor of hematogenous recurrence of gastric caner [J ]. J Surg O nco l, 2001, 78 (4) : 253- 258.
[5] N akata B, H irakaw a YS, Chung K, et al. SerumCA 125 level as a p redictor of peritoneal dissemination in patientsw ith gastric carcinoma [J ]. Cancer,1998,83 (12) : 2488- 2492.
[6] Pectasides D, Mylonalakis A , Kostopoulou M , et al.CEA , CA 1929, and CA 250 in monitor- ing gastric carcinoma [J ]. Am J Clin O ncol, 1997, 20 (4) : 348 -353.
[7] Pectasides D, M ylonalak is A , Ko stopoulouM , et al.CEA , CA 19-9, and CA 50 in monitoring gastric carcinoma [J ]. Am J Clin Oncol, 1997, 20 (4) : 348 -353.
[8] Nakata B, Chung K, M uguruma K, et al. Changes in tumo r marker levels as a predictor of chemotherapeutic effect in patients with gastric carcinoma [J ]. Cancer, 1998, 83 (1) : 19- 24.
[9] GasparMJ, A rribas I, CocaMC, et al. Prognostic value of carcinoembryonic antig- en, CA 19- 9 and CA 72-4in gast ric carcinoma [J ]. Tumor Biol, 2001, 22 (5) :318- 322
[10] ColcherD, Hand PH,Nuti M, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells [ J ]. Proc Natl Acad Sci USA, 1981, 78 (5) : 3199-3203.
[11]张涛,袁振铎,张鑫.肿瘤标志物志朽CA72-4在胃癌诊断中的意义[J].中级医刊. 1998, 33;43-35.
[12]赵继宗,詹义华,陈规划等.血清肿瘤相关糖蛋白72的临床应用探讨[J].中国胃肠外科杂志,1999;2:177-179.
[13]陈玉,林庚金.血清CA72-4测定鉴别胃良、恶性病变的价值[J].中国内镜杂志,1999;5:37.
[14]Tian Xuezhi,AnM ei,Zhang Yan.V alue and significance of C A19-9 and CEA in serum of patients with gastrointestinal cancer[J].C ancer Research and Clinic , 2000,12(1):17-18.
[15]TocchiT ,Costa G ,Lepte L ,et al .The role of serum and gastric juice levels of CE-A,CA19-9, C A72-4 in patients with gastric cancer[J ]. J Cancer Res Ciln Oncol, 1998 ,124( 8):450- 455.
[16]施平凡.血清GPDA测定对肝血管瘤与肝癌鉴别诊断的价值[J].天津医药.1998,26(1):29
[17]丛静波,王志华,牛爱军,等.血清苷氨酰脯氨酸二肽氨基肽酶对胃癌诊断价值的探讨[J].上海医学检验杂志,2002 ,17 (2) :75-76.
[18] Liu HD, Ni RZ, Xiao MB et al. Clinical significance of serum GPDA-F determined by immu -noelectrophoresis in diagnosis of hepatocellular carcinoma. Ai Zheng[J] 2006; 25 (2):247-249.
[19] Li M, Ni R, Huang J et al. The value of serum GPDA-F for the diagnosis of primary hepatoce -llular carcinoma.Zhonghua Gan Zang Bing Za Zhi[J] 2000;8(3):139-141.
[20] Ren J ,Chen Z ,Fan DM,et al . Defection of circulating gastric carcinoma associated antigen MG7 - Ag in human sera using an established single determinant immuno - polymerase chain reaction technique[J ] . Cancer ,2000 ,88 (2) :280.
[21]姚生华,沈江帆.胃癌MG抗原IRMA临床应用价值的初步探讨[J].放射免疫学杂志,1996, 9(3):133
[22]Samloff M. Pepsinogen I and II : purification from gastric mucosa and radio immunoassay in serum [J ].Gast roenterology, 1982, 82 (1) : 26- 33.
[23]蒋孟军,肖志坚.胃癌患者血清胃蛋白酶原含量的检测及其临床意义[J].实用癌症杂志, 2000, 15 (1) : 40- 42.
[24] Paula J Waters et al .Ann clin biodom 1992:29;627-637.
[25]陈建华,徐勇,郑晓丰等.血清唾液检测对诊断消化性肿瘤的临床应用[J].实用临床医学.2007,8(6):28-30.
[26]徐永成,陈奇奥,孙敏.血清CEA、CA199、CA724和EMA联检对胃癌的诊价值[J].放射免疫学杂志[J]2007,20(3):285-286.
[27]王开明.胃癌的早期诊断和治疗进展[J]浙江临床医学,2002,4(6): 401.
[28]张汝建,卢兴梅,韩信义.胃癌HP感染与PCNA表答的关系系[J]山东医药,1998,38(6): 10.
[29]王涛,张蓓,王占民.人体胃癌及癌前病变p53和PCNA的免疫组化研究[J]山东医科大学学报,1998,36(3):246～249.
[30]Kang YH ,Lee HS,Kin W H .Promoter methylation and silencing of PTEN in gastric carcinoma.Lab Invest,2002,82(3):285—291.
[31]刘芬,于皆平,邓全军,等. PTEN在胃癌细胞中的表达及其CpG岛甲基化状态的研究[J ].肿瘤防治研究, 2006, 33 (9):632-634.
[32]Yang L,,Kuang LG,Zheng HC,et a1.PTEN encoding product:a marker for tumorigenesis and progression of gastric carcinoma .World J Gasroenterol,2003,9(1):35,39.
[33]刘蒿翎,陈振依.p53基因突变与早期谚断胃癌的研究[J]广西医学,1998,20(3):381～383.
[34]Wang W,Luo HS,Yu BP. Expression of NF2kappaB and human telomerase reverse transcri -ptase in gastric cancer and precancerous lesions[J]. World J Gastroenterol ,2004 ,10:177 - 181.
[35]Ahn MJ.Nob YH,Lee YS,et a1.Telomemse activity and its clinicopathological significance in gastric Cance[j] Eur J Cancer.1997.33(8):1309～131 3.